Clinical Trial Update: Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously [Phase 1]

View source ↗

Summary

Phase 1 single ascending-dose intravenous study evaluating safety, tolerability, and pharmacokinetics of GAP-134 in patients with arrhythmia; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arrhythmia

Drugs mentioned

• GAP-134

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Arrhythmia | Phase 1 | Status: COMPLETED